Trans-Diamminedichloroplatinum (II) Is Not an Antitumor Drug: Why? - Archive ouverte HAL Accéder directement au contenu
Chapitre D'ouvrage Année : 1996

Trans-Diamminedichloroplatinum (II) Is Not an Antitumor Drug: Why?

Marc Boudvillain
Rozenn Dalbies-Tran
Leng M.
  • Fonction : Auteur

Résumé

The clinical activity of the antitumor drug cis-diamminedichloroplatinum(II) (cis-DDP) is thought to be related to its ability to form bifunctional lesions in DNA. trans-Diamminedichloroplatinum(II) (trans-DDP), the stereoisomer of cis-DDP, is clinically ineffective, although it forms bifunctional cross-links in the in vitro reaction with DNA1–4. A question still unsolved is why only cis-DDP is an antitumor drug.
Fichier non déposé

Dates et versions

hal-02097755 , version 1 (12-04-2019)

Identifiants

  • HAL Id : hal-02097755 , version 1

Citer

Marc Boudvillain, Rozenn Dalbies-Tran, Leng M.. Trans-Diamminedichloroplatinum (II) Is Not an Antitumor Drug: Why?. Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, 2, Plenum Press, New'Tork, USA, pp.17-25, 1996. ⟨hal-02097755⟩
22 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More